PFE - Bristol Myers Squibb's Combo Therapy Shows Sustained Benefits Over Pfizer's Cancer Drug In Kidney Cancer Patients After 8 Years Of Followup | Benzinga

Bristol Myers Squibb & Co (NYSE:BMY) announced that Opdivo (nivolumab) plus Yervoy (ipilimumab) combination continued to demonstrate long-term survival results in the Phase 3 CheckMate -214 trial. 

The Opdivo/Yervoy combo reduced the risk of death by 28% in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC) vs. Pfizer Inc (NYSE:PFE) Sutent (sunitinib) after eight years, regardless of International Metastatic RCC Database Consortium risk group. 

The data will be presented at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium.

Also Read: Bristol Myers’ Lead Cancer Immunotherapy Shows Progression-Free Survival Versus Chemo In Certain Type Of Colorectal Cancer.

Among intermediate- and poor-risk patients ...

Full story available on Benzinga.com